Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Matinas BioPharma's price to sales ratio was 301.9× on Jan 31, 2024.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 301.9× | −24.4 |
| 2023 | Dec 29, 2023 | 326.3× | – |
See a number that looks wrong?